Ascorbic acid inhibits antitumor activity of bortezomib in vivo.

Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K (Impact Factor: 9.38). 05/2009; 23(9):1679-86. DOI: 10.1038/leu.2009.83
Source: PubMed

ABSTRACT Earlier studies have shown that ascorbic acid (vitamin C) inhibits bortezomib-induced cytotoxicity against cancer cells in vitro. However, the clinical significance of vitamin C on bortezomib treatment is unclear. In this study, we examined whether daily oral intake of vitamin C inhibits antimultiple myeloma (MM) activities of bortezomib. Vitamin C, at orally achievable concentrations, inhibited in vitro MM cell cytotoxicity of bortezomib and blocked its inhibitory effect on 20S proteasome activity. Specifically, plasma collected from healthy volunteers taking 1 g/day vitamin C reduced bortezomib-induced MM cell death in vitro. This antagonistic effect of vitamin C against proteasome inhibitors is limited to the boronate class of inhibitors (bortezomib and MG262). In vivo activity of this combination treatment was then evaluated using our xenograft model of human MM in SCID (severe combined immune-deficient) mice. Bortezomib (0.1 mg/kg twice a week for 4 weeks) significantly inhibits in vivo MM cell growth, which was blocked by oral vitamin C (40 mg/kg/day). Therefore, our results for the first time show that vitamin C can significantly reduce the activity of bortezomib treatment in vivo; and importantly, suggest that patients receiving treatment with bortezomib should avoid taking vitamin C dietary supplements.

Download full-text


Available from: Gullu Gorgun, Jul 09, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: The intracellular protein degradation system is critical for many cellular processes, including cell cycle regulation. The proteasomes are intracellular protein complexes that degrade polyubiquitinated proteins. Bortezomib (Velcade®) is a boronic acid dipeptide that directly binds to enzymatic complex to block chimotrypsin-like activity of proteasome and is the first FDA-approved proteasome inhibitor for multiple myeloma (MM) treatment. Bortezomib blocks degradation of multi-proteins, including regulators of cell cycle, anti-apoptosis, and inflammation, as well as immune surveillance. In MM cells, bortezomib directly induces cell stress response followed by activation of c-Jun NH2 terminal kinase/stress- activated protein kinase and triggers cell cycle arrest, followed by caspase-dependent apoptosis. Bortezomib also modulates activities of non-MM cellular components, including stromal cells and osteoblasts in the bone marrow milieu. Importantly, combination treatment strategies, including histone deacetylase inhibitors, Akt inhibitor, lenalidomide, heat shock protein 90 inhibitors, and aurora kinase inhibitors demonstrate significant anti-MM activities both in preclinical and clinical studies.
    01/1970: pages 29-42;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper summarizes the propagation characteristics of a 20 MHz channel at a carrier frequency of 3.676 GHz transmitted from a two-antenna base to a two-antenna mobile receiver. The experiments were conducted in a moderate density suburban setting outside Chicago, Illinois. The transmit and receive systems are described, as are the data collection procedures and data analysis. The results include path loss measurements and various metrics of the MIMO channel, such as channel impulse responses, rms delay spread, and other spatial characteristics.
    Vehicular Technology Conference, 2002. VTC Spring 2002. IEEE 55th; 02/2002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with leukemia often seek additional treatments not prescribed by their oncologist in an effort to improve their cancer treatment outcome or to manage symptoms. Complementary therapies are used in conjunction with traditional cancer treatments to decrease symptoms and side effects associated with cancer or cancer treatment, and to improve patients' overall quality of life. Complementary therapies are distinct from so-called 'alternative' therapies, which are unproven, ineffective and may postpone or interfere with mainstream cancer treatment. Complementary therapies are pleasant, inexpensive, nonpharmacologic and effective. For patients with leukemia, the complementary therapies that are always appropriate include mind-body interventions, such as self-hypnosis, meditation, guided imagery and breath awareness. Massage and reflexology (foot massage) decrease symptoms with effects lasting at least 2 days following treatment. Acupuncture is very beneficial for symptom management without adverse consequences. Physical fitness with regular exercise and healthy dietary habits can significantly decrease side effects of cancer treatments and may prolong survival. Botanical extracts and vitamin supplements may interfere with active cancer treatments, and should be discussed with the oncologist or pharmacist before use.
    Expert Review of Anti-infective Therapy 09/2009; 9(9):1241-9. DOI:10.1586/era.09.100 · 2.28 Impact Factor